| Not Yet Recruiting | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma NCT07510100 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma NCT05874193 | Cristiana Costa Chase, DO | Phase 2 |
| Recruiting | A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma NCT07493135 | Suzhou Immunofoco Biotechnology Co., Ltd | EARLY_Phase 1 |
| Not Yet Recruiting | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma NCT07454187 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Sta NCT07391657 | AstraZeneca | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multi NCT07284758 | C4 Therapeutics, Inc. | Phase 2 |
| Recruiting | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia NCT07509086 | The First Hospital of Jilin University | Phase 2 |
| Not Yet Recruiting | Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refra NCT07195617 | Guangzhou Bio-gene Technology Co., Ltd | N/A |
| Recruiting | ELISA in Relapsed/Refractory MM NCT06832865 | Massachusetts General Hospital | Phase 2 |
| Recruiting | A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia NCT06730256 | The First Affiliated Hospital of Soochow University | EARLY_Phase 1 |
| Not Yet Recruiting | LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma NCT06888752 | First Affiliated Hospital of Wenzhou Medical University | N/A |
| Recruiting | A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma NCT06791681 | Chunrui Li | EARLY_Phase 1 |
| Recruiting | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multip NCT06668792 | Biocad | Phase 2 |
| Recruiting | a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia NCT06718270 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Recruiting | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Pa NCT06669247 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Not Yet Recruiting | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell L NCT06655519 | Peking University People's Hospital | Phase 1 |
| Not Yet Recruiting | A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Mul NCT06659770 | CARsgen Therapeutics Co., Ltd. | — |
| Not Yet Recruiting | LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma NCT06472479 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Recruiting | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM NCT06515262 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | N/A |
| Not Yet Recruiting | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. NCT06369935 | Peking University People's Hospital | — |
| Recruiting | A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexameth NCT06508983 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 3 |
| Recruiting | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma NCT06279026 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | N/A |
| Recruiting | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors NCT06783816 | Shanxi Bethune Hospital | N/A |
| Recruiting | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) NCT05862012 | Ichnos Sciences SA | Phase 1 |
| Recruiting | A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma NCT06049290 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Withdrawn | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Ref NCT05980507 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Withdrawn | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT04998747 | Amgen | Phase 1 |
| Recruiting | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) NCT05850234 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Cevostamab Following CAR T Cell Therapy for RRMM NCT05801939 | University of Pennsylvania | Phase 2 |
| Unknown | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma NCT05857982 | Second Affiliated Hospital of Soochow University | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple My NCT05839626 | Sanofi | Phase 1 / Phase 2 |
| Recruiting | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignan NCT05880043 | GI Cell, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Part NCT05704049 | Sanofi | Phase 2 |
| Recruiting | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05759793 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma NCT05722418 | Caribou Biosciences, Inc. | Phase 1 |
| Withdrawn | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Mye NCT05461209 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV- NCT05259839 | AbbVie | Phase 1 |
| Terminated | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812 | Ichnos Sciences SA | Phase 1 / Phase 2 |
| Terminated | BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma NCT05376345 | Weijun Fu | Phase 1 |
| Not Yet Recruiting | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma NCT05498545 | Second Affiliated Hospital of Xi'an Jiaotong University | Phase 1 |
| Active Not Recruiting | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhi NCT05338775 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Ref NCT05308654 | AbbVie | Phase 1 |
| Unknown | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# NCT05266768 | Chunrui Li | Phase 1 |
| Completed | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# NCT05270928 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Active Not Recruiting | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383 NCT05286229 | AbbVie | Phase 1 |
| Recruiting | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721 | Chunrui Li | Phase 1 |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Terminated | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT04896658 | University of Maryland, Baltimore | Phase 1 / Phase 2 |
| Recruiting | A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myelom NCT05160584 | Janssen Pharmaceutica N.V., Belgium | — |
| Recruiting | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Pl NCT04973605 | BeOne Medicines | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractor NCT05000450 | Allogene Therapeutics | Phase 1 / Phase 2 |
| Completed | agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma NCT04754100 | MiNK Therapeutics | Phase 1 |
| Terminated | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) NCT06655818 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple NCT04762745 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Terminated | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Mye NCT04649060 | Oncopeptides AB | Phase 3 |
| Completed | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma NCT04176380 | Rapa Therapeutics LLC | Phase 2 |
| Unknown | A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-target NCT04601935 | Weijun Fu | Phase 1 |
| Suspended | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma NCT04505813 | NexImmune Inc. | Phase 1 / Phase 2 |
| Terminated | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT NCT04150965 | Multiple Myeloma Research Consortium | Phase 1 / Phase 2 |
| Unknown | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Mult NCT04309981 | Sara V. Latorre | Phase 1 / Phase 2 |
| Terminated | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacesta NCT04171843 | Precision BioSciences, Inc. | Phase 1 |
| Terminated | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma NCT04635735 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Terminated | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myel NCT04142619 | Cellectis S.A. | Phase 1 |
| Terminated | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants NCT06160609 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple M NCT04093596 | Allogene Therapeutics | Phase 1 |
| Completed | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple NCT03934684 | Amgen | Phase 4 |
| Completed | Myeloma-Developing Regimens Using Genomics (MyDRUG) NCT03732703 | Multiple Myeloma Research Consortium | Phase 1 / Phase 2 |
| Terminated | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myel NCT03590652 | University of California, San Diego | Phase 2 |
| Terminated | Study Evaluating AMG 424 in Subjects With Multiple Myeloma NCT03445663 | Xencor, Inc. | Phase 1 |
| Completed | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma NCT03489525 | MedImmune LLC | Phase 1 |
| Terminated | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma NCT03201250 | University of Nebraska | Phase 1 / Phase 2 |
| Completed | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment NCT03450057 | Hellenic Society of Hematology | Phase 2 |
| Terminated | A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in S NCT03287908 | Amgen | Phase 1 |
| Completed | Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma NCT03309111 | Ichnos Sciences SA | Phase 1 |
| Terminated | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myelom NCT03318861 | Kite, A Gilead Company | Phase 1 |
| Terminated | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selecte NCT03196947 | Allarity Therapeutics | Phase 1 / Phase 2 |
| Completed | NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" NCT03169361 | Takeda | — |
| Completed | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexameth NCT02755597 | AbbVie | Phase 3 |
| Completed | A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R NCT02608515 | Genesis Pharma S.A. | — |
| Completed | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Stan NCT01794507 | AbbVie | Phase 1 |
| Completed | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma NCT01794520 | AbbVie | Phase 1 / Phase 2 |
| Completed | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma NCT01849848 | SymBio Pharmaceuticals | Phase 2 |
| Completed | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma NCT01102426 | PharmaMar | Phase 3 |
| Completed | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI NCT00697684 | Beth Israel Deaconess Medical Center | Phase 1 |